Marshall Wace
SGMO

Marshall Wace’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Marshall Wace’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-303,862
Closed -$76K – 3676
2026
Q1 		$76K Buy
+303,862
New +$121K ﹤0.01% 2931
2025
Q2 		– Sell
-651,906
Closed -$430K – 3114
2025
Q1 		$430K Buy
651,906
+314,776
+93% +$333K ﹤0.01% 2136
2024
Q4 		$344K Sell
337,130
-2,016,626
-86% -$3.69M ﹤0.01% 2192
2024
Q3 		$2.05M Buy
2,353,756
+1,777,537
+308% +$1.3M ﹤0.01% 1355
2024
Q2 		$207K Buy
576,219
+207,476
+56% +$112K ﹤0.01% 2288
2024
Q1 		$247K Buy
+368,743
New +$267K ﹤0.01% 2172
2020
Q4 		– Sell
-11,127
Closed -$105K – 2141
2020
Q3 		$105K Buy
+11,127
New +$120K ﹤0.01% 1515
2020
Q2 		– Sell
-1,363,039
Closed -$8.68M – 1898
2020
Q1 		$8.68M Buy
1,363,039
+1,033,713
+314% +$7.67M 0.09% 240
2019
Q4 		$2.76M Buy
329,326
+296,968
+918% +$2.73M 0.02% 718
2019
Q3 		$293K Buy
+32,358
New +$363K ﹤0.01% 1210
2019
Q1 		– Sell
-712,657
Closed -$8.18M – 2030
2018
Q4 		$8.18M Buy
712,657
+699,089
+5,152% +$8.68M 0.08% 302
2018
Q3 		$230K Buy
+13,568
New +$206K ﹤0.01% 1048
2017
Q3 		– Sell
-56,314
Closed -$507K – 409
2017
Q2 		$507K Buy
+56,314
New +$361K 0.02% 240

Other funds holding SGMO

NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
AIM
Axiom Investment Management New York $150M AUM
FTUS
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Marshall Wace's SGMO Position: Q2 2026 in Review

Marshall Wace sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 303,862 shares — an estimated $76K sold.

Marshall Wace first reported a position in SGMO in Q2 2017 and held it in 13 quarters. The position peaked at $8.68M in Q1 2020. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

  • Marshall Wace reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 303,862 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $76K.
  • Marshall Wace first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 13 quarters.
  • Marshall Wace's SANGAMO THERAPEUTICS INC position peaked at $8.68M in Q1 2020.
  • 6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.